{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:51:00Z","timestamp":1781941860215,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007334","name":"Ministry of Health and Family Welfare","doi-asserted-by":"publisher","award":["2710092954"],"award-info":[{"award-number":["2710092954"]}],"id":[{"id":"10.13039\/501100007334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007334","name":"Ministry of Health and Family Welfare","doi-asserted-by":"publisher","award":["RS-2023-00282592"],"award-info":[{"award-number":["RS-2023-00282592"]}],"id":[{"id":"10.13039\/501100007334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jtha.2025.12.023","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:40:16Z","timestamp":1770223216000},"page":"1318-1326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A first-in-human study assessing the safety, pharmacokinetics, and pharmacodynamics of TU7710, a recombinant factor VIIa\u2013transferrin fusion protein, in warfarin-pretreated healthy male participants"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4032-6112","authenticated-orcid":false,"given":"Byungwook","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-3493","authenticated-orcid":false,"given":"Jisoo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3973-047X","authenticated-orcid":false,"given":"Jaegu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6830-1124","authenticated-orcid":false,"given":"Minsun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7689-8440","authenticated-orcid":false,"given":"Ji Hyun","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7949-7051","authenticated-orcid":false,"given":"Heeyeon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0921-7225","authenticated-orcid":false,"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.12.023_bib1","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.12.023_bib2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/asheducation-2016.1.657","article-title":"Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches","volume":"2016","author":"Meeks","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2025.12.023_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1019275","article-title":"Hemophilia a patients with inhibitors: mechanistic insights and novel therapeutic implications","volume":"13","author":"Luo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2025.12.023_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102670","article-title":"Recombinant factor VIIa: new insights into the mechanism of action through product innovation","volume":"9","author":"Escobar","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.12.023_bib5","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/clpt.1994.80","article-title":"Pharmacokinetics and pharmacodynamics of recombinant factor VIIa","volume":"55","author":"Lindley","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2025.12.023_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.thromres.2011.02.018","article-title":"Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa","volume":"128","author":"Karpf","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.12.023_bib7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.thromres.2014.12.018","article-title":"Enhanced pharmacokinetics of factor VIIa as a monomeric Fc fusion","volume":"135","author":"Salas","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.12.023_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","article-title":"The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy","volume":"91","author":"Sockolosky","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jtha.2025.12.023_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10673","article-title":"Hemostats in the clinic","volume":"9","author":"Joshi","year":"2024","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.jtha.2025.12.023_bib10","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/hae.12994","article-title":"TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity","volume":"22","author":"Mahlangu","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.12.023_bib11","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/jth.12409","article-title":"Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers","volume":"11","author":"Golor","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.12.023_bib12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00001721-199811000-00003","article-title":"The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0","volume":"9","author":"Erhardtsen","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2025.12.023_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-0037-1615148","article-title":"Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol","volume":"80","author":"Girard","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.12.023_bib14","first-page":"97","article-title":"Correlation between PT\/INR and APTT in patients on warfarin: a study at a tertiary care teaching hospital","volume":"6","author":"Attanayake","year":"2023","journal-title":"Asian Hematol Res J"},{"key":"10.1016\/j.jtha.2025.12.023_bib15","first-page":"964","article-title":"Effect of warfarin on the activated partial thromboplastin time","volume":"20","author":"Hauser","year":"1986","journal-title":"Drug Intell Clin Pharm"},{"key":"10.1016\/j.jtha.2025.12.023_bib16","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archinte.158.10.1140","article-title":"Effect of warfarin on activated partial thromboplastin time in patients receiving heparin","volume":"158","author":"Kearon","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2025.12.023_bib17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.mbc.0000169218.15926.34","article-title":"A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects","volume":"16","author":"Fridberg","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2025.12.023_bib18","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/j.1538-7836.2011.04344.x","article-title":"Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects","volume":"9","author":"Moss","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.12.023_bib19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1538-7836.2012.04667.x","article-title":"Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia","volume":"10","author":"Mahlangu","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.12.023_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1538-7836.2008.03253.x","article-title":"Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects","volume":"7","author":"Moss","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.12.023_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2125.2007.03030.x","article-title":"Overview of the human pharmacokinetics of recombinant activated factor VII","volume":"65","author":"Klitgaard","year":"2008","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:18:08Z","timestamp":1781939888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1538783626000395"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.12.023","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A first-in-human study assessing the safety, pharmacokinetics, and pharmacodynamics of TU7710, a recombinant factor VIIa\u2013transferrin fusion protein, in warfarin-pretreated healthy male participants","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}